dcvax [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

[[DCVax]](®) (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering [[dendritic cell vaccine]]s for a variety of [[cancer]]s, including [[glioblastoma multiforme]] (GBM).
----
DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated. DCVax-Lung recently received approval from the US FDA for phase I clinical trials
((Knutson KL. Technology evaluation: DCVax, Northwest Biotherapeutics. Curr Opin
Mol Ther. 2002 Aug;4(4):403-7. PubMed PMID: 12222879.
)).

see [[DCVax-L]].